Ostarine held the promise of profound medical treatments. Something unexpected happened on the way to F.D.A. approval.

Opening up about drug pricing decisions is not optional for biopharma anymore. For the sake of credibility, companies should ...

The Trump administration is delaying the release of TrumpRx, an online platform that lets people buy prescription drugs ...

While 2025 was the year of disruption for Trump’s pharma policies, we expect 2026 to be the year of truth: will the US ...

In this article, we will look at the 10 Best Performing Pharma Stocks in 2025. On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss ...

Mike Feuz is an economic consultant by day and a research associate for the think tank Free the People by night. He has a master’s degree in economics from George Mason University. For years, ...

NEW YORK, Nov. 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ: ATYR) of a class action securities lawsuit. CLASS DEFINITION: ...

AFTER AMERICA, China is the world’s largest developer of new medicines. Its companies ran nearly a third of the planet’s clinical trials last year. That is up from just 5% a decade before (see chart 1 ...

A federal judge officially approved drugmaker Purdue Pharma's $7.4 billion deal to settle thousands of lawsuits over the toll of the opioid epidemic and pay victims, prosecutors in the case told USA ...

This is read by an automated voice. Please report any issues or inconsistencies here. Federal judge approved Purdue Pharma settlement requiring the Sackler family to contribute up to $7 billion and ...

NEW YORK (AP) — A federal bankruptcy court judge on Friday said he will approve OxyContin-maker Purdue Pharma’s latest deal to settle thousands of lawsuits over the toll of opioids that includes some ...

Medicine has entered the age of AI. The same way ChatGPT can generate hundreds of social posts in seconds, AI models are churning out drug candidates at record pace. Hundreds of startups and big ...